The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Amphotericin B Pharmacokinetics in Humans
Open accessAbstract
The pharmacokinetics of amphotericin B were studied in two patients at the conclusion of long-term therapy for disseminated histoplasmosis. The distribution kinetics of this drug were adequately described by a three-compartment mamillary model with a total distribution volume averaging 4 liters/kg. The elimination phase half-life of amphotericin B was approximately 15 days, reflecting slow release of amphotericin B from a peripheral compartment. In accordance with previous reports, renal excretion accounted for only 3% of total amphotericin B elimination. The pharmacokinetic model for one of the patients also was used to compare the simulated amphotericin B serum levels that would be expected if initial therapy followed two recommended regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma and Tissue Protein Binding of Drugs in Pharmacokinetics
Jusko, W. J., & Gretch, M. (1976) · Drug Metabolism Reviews · doi:10.3109/03602537608995839 · Cited by 372
A Pharmacologic Guide to the Clinical Use of Amphotericin B
Bindschadler, D. D., & Bennett, J. E. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/120.4.427 · Cited by 232
Self-citationChemotherapy of Systemic Mycoses
Bennett, J. E. (1974) · New England Journal of Medicine · doi:10.1056/nejm197401032900107 · Cited by 220
Self-citationTreatment of disseminated mycotic infections
Drutz, D. J., Spickard, A., Rogers, D. E., & Koenig, M. G. (1968) · The American Journal of Medicine · doi:10.1016/0002-9343(68)90075-2 · Cited by 144
Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance
Block, E. R., BENNETT, J. E., LIVOTI, L. G., KLEIN, W. J., MacGREGOR, R. R., & HENDERSON, L. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-5-613 · Cited by 129
Self-citationThe effect of diphenylhydantoin on thyroxine metabolism in man
Larsen, P. R., Atkinson, A. J., Wellman, H. N., & Goldsmith, R. E. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106339 · Cited by 119
Self-citationSome aspects of the absorption, distribution, and excretion of amphotericin B in man.
Db, L. (1958) · PubMed · Cited by 117
CLEARANCE AND BIOLOGIC HALF-LIFE AS INDICES OF INTRINSIC HEPATIC METABOLISM
Perrier, D. G., & Gibaldi, M. (1974) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29960-8 · Cited by 109
Amphotericin B Serum Concentrations During Therapy
Fields, B. T., Bates, J. H., & Abernathy, R. S. (1970) · Applied Microbiology · doi:10.1128/am.19.6.955-959.1970 · Cited by 68
Amphotericin B Therapy in an Anephric Patient
Feldman, H. A., Hamilton, J. D., & Gutman, R. (1973) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.4.3.302 · Cited by 38
Cited by
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Metadata
- Authors
- Atkinson, A. J., & Bennett, J. E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1978-02
- Volume
- 13
- Issue
- 2
- Pages
- 271-276
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2083356192
- Cited by
- 267
- References
- 10
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.